Clinical Trials Logo

Glioblastoma, Adult clinical trials

View clinical trials related to Glioblastoma, Adult.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04116658 Active, not recruiting - Glioblastoma, Adult Clinical Trials

First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

ROSALIE
Start date: July 13, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.

NCT ID: NCT03665545 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

IMA950-106
Start date: October 25, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Monocentric randomized phase I/II trial, including 24 patients diagnosed with relapsing glioblastoma (GBM) irrespective of MGMT and IDH gene status. Following diagnosis of relapsing glioblastoma by either brain CT scan or MRI, patients will be randomized in 2 arms: 1. Arm 1: IMA950 mixed with Poly-ICLC administered subcutaneously 2. Arm 2: Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly-ICLC administered subcutaneously The first phase of treatment will last 6 weeks, then surgery will be performed (done if clinically possible ad indicated). In case of available brain tissue, extensive analysis of the tumor immune response will be performed. Assessment of systemic immune response by PBMC immunomonitoring will be systematically done before and after surgery.

NCT ID: NCT03181477 Active, not recruiting - Glioblastoma, Adult Clinical Trials

Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas

Glio-SIB-Up
Start date: April 7, 2017
Phase: N/A
Study type: Interventional

Glioblastoma (GBM) is the most aggressive and most frequent brain tumour. Approximately four people per 100,000 inhabitants are diagnosed with this disease every year. The standard treatment comprises surgical resection (whenever possible), normofractionated radiotherapy at a dose of 60Gray (Gy) and temozolomide (TMZ). Median overall survival in these patients is 14.6 months [13.2-16.8]. In a previous phase I clinical trial, dose escalation tolerance using simultaneous-integrated boost intensity-modulated radiation therapy (SIB-IMRT) technic has been evaluated. The investigator demonstrated that SIB-IMRT until a dose of 80Gy in 32 daily fractions, associated with TMZ is feasible and well tolerated by patients with glioblastoma. The aim of this present phase II clinical trial is to evaluate the overall survival at 18 months for patients with glioblastoma receiving TMZ, according to standard protocol, associated to radiotherapy delivered at 80Gy using SIB-IMRT technic. The first planning target volume (PTV), including oedema and tumour highlighted on T2 flair magnetic resonance imaging (MRI) sequences, will receive 60.8Gy in 32 daily fractions. The second PTV, including tumour highlighted on T1 MRI sequences, will receive 80.0Gy in 32 daily fractions. Secondary objectives are tolerance, survival free progression and quality of live evaluations. Sixty seven patients will be enrolled in this present trial.

NCT ID: NCT02974738 Active, not recruiting - Solid Tumor Clinical Trials

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Start date: December 7, 2016
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors